News >

John Theurer Cancer Center Evaluating Personalized Cancer Vaccine in High-Risk Melanoma

Brittany Cote
Published: Tuesday, Mar 03, 2020

Andrew L. Pecora, MD

Andrew L. Pecora, MD
An ongoing clinical trial will assess whether the adjuvant combination of the personalized cancer vaccine mRNA-4157 and pembrolizumab (Keytruda) improves recurrence-free survival (RFS) compared with pembrolizumab alone in patients with complete resection of cutaneous melanoma and a high-risk of recurrence.1

Seventeen sites are enrolling patients on the multicenter, international trial KEYNOTE-942 trial (NCT03897881), including John Theurer Cancer Center.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication